Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7567655 | 0.96 | MAPT (0.47) | MAPTKDM4EKMT2AMEN1ALOX15 | |
| SCHEMBL4671441 | 0.88 | KDM4E (0.50) | MAPTKDM4EKMT2AMEN1ALOX15 | |
| SCHEMBL234027 | 0.86 | KDM4E (0.55) | MAPTKDM4EKMT2AMEN1ALOX15 | |
| SCHEMBL28283233 | 0.81 | KDM4E (0.55) | MAPTKDM4EKMT2AMEN1ALOX15 | |
| SCHEMBL6538246 | 0.80 | KDM4E (0.50) | MAPTKDM4EKMT2AMEN1ALOX15 | |
| SCHEMBL317949 | 0.80 | MAPT (0.50) | MAPTKDM4EKMT2AMEN1ALOX15 | |
| SCHEMBL8480122 | 0.78 | KDM4E (0.48) | MAPTKDM4EKMT2AMEN1ALOX15 | |
| SCHEMBL6538791 | 0.78 | KDM4E (0.48) | MAPTKDM4EKMT2AMEN1ALOX15 | |
| SCHEMBL4133061 | 0.77 | KDM4E (0.47) | MAPTKDM4EKMT2AMEN1ALOX15 | |
| SCHEMBL1144592 | 0.77 | ALDH1A1 (0.47) | MAPTKDM4EKMT2AMEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0848696-B1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020082419-A1 | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6313163-B1 | ADMINISTERING 2,4-PENTADIENOIC ACID DERIVATIVE FOR THERAPY OF DISEASE OR CONDITION RESPONSIVE TO THERAPY BY RETINOIDS | ALLERGEN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6114533-A | A COMPOUNDS HAVING A 2,4-PENTADIENOIC ACID OR 2,4-PENTADIENOIC ACID ESTER FUNCTION WHICH IS SUBSTITUTED IN THE 5-POSITION WITH TETRAHYDROQUINOLINYL GROUP | ALLERGAN SALES, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-6034242-A | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-5917082-A | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1999008992-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5817836-A | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN (US) | 1998-10-06 | — | — | US | disclosed |
| US-5780647-A | 2,4-Pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0848696-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-06-24 | — | — | EP | disclosed |
| US-5675033-A | FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
| US-5663367-A | REGULATOR OF CELL PROLIFERATION AND DIFFERENTIATION; TREATMENT OF SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| WO-1996039374-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082419-A1 | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | RXRA, RXRB, CBR1 | MAPT 4880/4885KDM4E 2690/4885KMT2A 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.